Liraglutide is used in the treatment of Type 2 Diabetes Mellitus. It is used along with diet and exercise to improve blood sugar control in adults with type 2 diabetes.
🛒 How to order this item?
100% Genuine Products, Guaranteed
Safe & Secure Payments, Always
Fast, Secure & Efficient Delivery
Proper Packaging
Show More
Victoza Solution for Injection PEN (PREFILLED) contains Liraglutide, classified within the group of medications known as Antidiabetics. This pre-filled pen is prescribed for managing type 2 diabetes mellitus. Its primary role is to help lower elevated blood sugar levels and moderate the pace at which food moves through the stomach, consequently aiding in the prevention of heart disease. Victoza Solution for Injection is employed as a standalone treatment when blood sugar remains uncontrolled despite efforts involving diet, physical activity, and other oral antidiabetic drugs like metformin, pioglitazone, sulfonylurea (such as glimepiride, glipizide), as well as sodium-glucose cotransporter 2 inhibitors (SGLT2i) such as empagliflozin and dapagliflozin, and/or insulin. Type 2 Diabetes mellitus, a chronic condition characterized by symptoms like excessive thirst, frequent urination, heightened appetite, unintentional weight loss, weakness, and blurred vision, is caused by elevated blood sugar levels.
Liraglutide functions by assisting the pancreas in releasing appropriate insulin quantities in response to elevated blood sugar levels. This insulin is then directed from the bloodstream into body tissues for energy utilization, resulting in reduced blood sugar levels. Additionally, Liraglutide's effects include a slowing of stomach emptying, contributing to decreased appetite, and aiding in weight control.
Victoza Solution for Injection is contraindicated for patients with type 1 diabetes, diabetic ketoacidosis (a diabetes complication characterized by high blood sugar and labored breathing), severe gastrointestinal issues, inflammatory bowel disease, severe liver disease, or heart failure. Prior to commencing usage of Victoza Solution for Injection, it is essential to notify your healthcare professional of any thyroid disorders like an enlarged thyroid gland or a history of pancreatic diseases such as pancreatitis.
This medication is not recommended for pregnant or breastfeeding women, and special caution is advised for elderly patients aged 65 and above. Seeking medical guidance before initiation is highly recommended. Common adverse effects associated with Victoza Solution for Injection) encompass nausea, diarrhea, vomiting, and episodes of low blood sugar. In case these symptoms worsen, it's advised to consult your healthcare provider.
Consumption of alcohol is not recommended during treatment with Liraglutide due to the increased risk of severe side effects.
Liraglutide is not recommended to be used if you are pregnant as it may harm your developing child. Your doctor will suggest another medicine with similar therapeutic effects in such cases.
It is not known whether Liraglutide passes into breast milk. Hence is not recommended for use during breastfeeding. Consult your doctor if you are breastfeeding.
Victoza Solution for Injection could potentially lead to symptoms of low blood sugar, including cold sweat, pale skin, headache, rapid heartbeat, nausea, increased hunger, vision changes, drowsiness, weakness, nervousness, confusion, difficulty concentrating, and trembling. If these signs arise, refrain from driving or using machinery.
Victoza Solution for Injection should be used with caution in patients with kidney problems. Consult your doctor before using VICTOZA 6MG/ML PEN(PREFILLED).
Victoza Solution for Injection is not recommended for use in patients with severe liver disease. Consult your doctor before using Victoza Solution for Injection.
Victoza Solution for Injection operates by aiding the pancreas in releasing an appropriate quantity of insulin in response to elevated blood sugar levels. This insulin is subsequently transported from the bloodstream to body tissues, where it is utilized as an energy source. This process contributes to the reduction of blood sugar levels. Additionally, the medication has the effect of slowing down the emptying process of the stomach, leading to a decrease in appetite and subsequently helping to prevent weight gain.
Diabetes mellitus, also known as adult-onset diabetes, is a metabolic disorder characterized by elevated blood sugar levels. This condition typically falls under type 2 diabetes and arises when either the insulin hormone, produced by the pancreas's beta cells, encounters resistance in its function of breaking down glucose for energy production (insulin resistance), or the pancreas generates insufficient or no insulin at all. While this ailment is more common in individuals over the age of 40, it can also manifest in childhood based on specific risk factors. Treatment approaches encompass oral medications aimed at lowering glucose levels and the administration of insulin injections.
Victoza Solution for Injection 3 ml is classified as an anti-diabetic medication, primarily employed in managing type 2 diabetes mellitus among individuals aged 10 years and older.
Liraglutide incorporates acylated GLP-1, an inherent incretin hormone, which assumes the role of a GLP-1 receptor agonist. Through a glucose-dependent mechanism, activation of the GLP-1 receptor triggers an increase in insulin production and a reduction in the secretion of glucagon. Additionally, the process of gastric emptying is delayed, resulting in decreased blood glucose levels following meals. This leads to the reduction of both premeal and postprandial glucose levels, and it contributes to a decrease of approximately 1 percent in HbA1c levels.
For adults with Type 2 diabetes mellitus, the subcutaneous administration of Liraglutide is recommended as an adjunct to treatment. The dosing regimen is as follows:
For children (those under 18 years of age), the safety and efficacy of Liraglutide have not been established.
In individuals with renal impairment, no dose adjustment is required.
Liraglutide can be administered once daily at any time of the day, regardless of meals. The injection can be given subcutaneously in the abdomen, thigh, or upper arm. The site and timing of injection can be altered without necessitating a change in the dosage.
If a dose is missed, the regular once-daily schedule should be resumed with the next planned dose. It's important not to administer an additional or higher dose to compensate for the missed one. If more than three days have passed since the missed dose, resuming therapy at the 0.6 mg/day dose is recommended to prevent gastrointestinal symptoms.
Drug-Drug Interactions: Victoza Solution for Injection 3ml has the potential to interact with other anti-diabetic medications like insulin glargine and insulin degludec, as well as hormones such as levothyroxine, corticosteroids like prednisone, psychiatric drugs like olanzapine, antibiotics such as ciprofloxacin, hypertension medications like propranolol and metoprolol, and glaucoma eye drops containing timolol.
Drug-Food Interaction: Limiting alcohol intake is advisable, as it can affect blood sugar levels. Furthermore, it's recommended to avoid fatty foods and incorporate healthy carbohydrates into your diet.
Drug-Disease Interaction: Before using Victoza Solution for Injection 3 ml, it's important to inform your doctor if you have a medical history of allergic reactions to medications, heart, kidney, or liver diseases, pancreatitis (inflammation of the pancreas), stomach disorders like gastroparesis (delayed gastric emptying), high cholesterol levels, gallbladder problems, or depression. Notably, this medication is contraindicated in patients with multiple endocrine neoplasia type 2 (tumors affecting the thyroid and parathyroid glands), as well as individuals with a personal or family history of thyroid cancer. It's crucial to communicate such information to your healthcare provider to ensure safe and effective use of the medication.
The medication should not be used in individuals who have previously experienced a significant hypersensitivity reaction to any of the components of the product.
Furthermore, it is contraindicated in individuals with type 1 diabetes mellitus, diabetic ketoacidosis, severe renal impairment, end-stage renal disease, and during pregnancy and lactation.
It's crucial to note that Victoza Solution for Injection 3 ml is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or in those diagnosed with multiple endocrine neoplasia syndrome type 2 (MEN 2). These contraindications are in place to ensure the safety and well-being of individuals considering the use of this medication. Always consult your healthcare provider for guidance on the appropriateness of this medication for your specific health circumstances.
The obstetrics category C classification indicates that Victoza Solution for Injection 3ml falls into a category where animal studies have demonstrated potentially harmful effects on the fetus, including teratogenic (causing birth defects) or embryocidal (causing harm to the developing embryo) effects. However, there haven't been controlled studies conducted on pregnant women, and there's also a lack of studies involving both women and animals.
The use of drugs during pregnancy, including Victoza, should be carefully considered. The decision to administer such medications to pregnant women should be based on a thorough assessment of potential benefits versus risks. The healthcare provider will weigh the potential advantages of using the medication against the potential risks it might pose to both the mother and the developing fetus.
Ultimately, the well-being of both the pregnant woman and the fetus is of utmost importance, and medical guidance should always be sought to make informed decisions about medication use during pregnancy.
The usage of Victoza Solution for Injection 3ml should be approached with caution in the presence of certain medical conditions:
Individuals with these conditions should approach the use of Victoza Solution for Injection 3ml under the guidance of a healthcare provider to ensure safe and appropriate usage.
Store the pen in the refrigerator. When refrigeration is not possible, you can also keep your pen at room temperature (less than 30°C) for up to 2 weeks. Do not freeze it.
Disclaimer:
ePharma sole intention is to ensure that its consumers get proper
information as musch as possible. Although we do not guarantee the
accuracy and the completeness of the information that provided and
here information is for informational purposes only.
The information contained herein should NOT be used as a substitute
for the advice of a qualified physician. This may not cover
everything about particular health conditions,
lab tests, medicines, all possible side effects, drug interactions,
warnings, alerts, etc. Please consult your healthcare professional
and discuss all your queries related to any disease or medicine. We
intend to support, not replace, the doctor-patient relationship.